A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy ...

A new study employing novel single-cell multimodal data revealed key insights into the tumor microenvironment predictive of NSCLC treatment response.

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that it will present latest clinical ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Each year, 50,000 new lung cancer cases are diagnosed in France, with non–small cell lung cancer (NSCLC ... Among the major advances presented at the congress were the findings from the ...

This breakthrough not only advances the treatment of non-small cell lung cancer but also marks a significant milestone in global oncology immunotherapy." "The interim analysis results from the ...

Christopher Danes, PhD, discusses how patient and caregiver priorities and concerns vary during the course of treatment for non–small cell lung cancer.

The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell ...

AbbVie has received accelerated approval from the U.S. Food and Drug Administration (FDA) for EMRELIS (telisotuzumab vedotin-tllv) for the treatment of adult patients with ...

This breakthrough not only advances the treatment of non-small cell lung cancer but also marks a significant milestone in global oncology immunotherapy." ...